Ribosomal protein L7a pseudogene 6 (RPL7AP6)

RPL7AP6 is a *processed pseudogene* of the ribosomal protein L7a. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional, having lost their protein-coding capability, usually due to mutations, deletions, or insertions. RPL7AP6 does not produce a functional protein and therefore does not possess molecular activity, does not act as a receptor, enzyme, transporter, or true therapeutic target, and is not involved in typical biological functions attributed to ribosomal proteins. While functional RPL7A is responsible for being a part of the large 60S ribosomal subunit and is involved in protein synthesis, RPL7AP6 itself is simply a non-functional DNA remnant. Generally, pseudogenes are not considered direct therapeutic targets. However, recent studies of some pseudogenes have shown regulatory roles in certain diseases, including cancer, as competitive endogenous RNAs or through other RNA-mediated mechanisms. These roles are gene- and context-specific, and there is currently no evidence suggesting that RPL7AP6 itself functions as a biomarker, disease effector, or therapeutic target. RPL7AP6 is not a true therapeutic target. It does not encode a functional protein. There are no known drugs, biomarkers, or safety concerns associated. Its primary significance is as a genomic marker or for evolutionary studies, not as a molecule of direct biomedical relevance. If you are looking for biological function, therapeutic relevance, or molecular targeting, this gene should generally be excluded from such consideration. For molecular, biomarker, or pharmacological work, refer to the canonical ribosomal protein L7a (RPL7A), not its pseudogene variants.

Other names

RPL7A_27_1386RPL7AP6